These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 1710991)
21. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. Noguchi CT; Rodgers GP; Serjeant G; Schechter AN N Engl J Med; 1988 Jan; 318(2):96-9. PubMed ID: 2447498 [No Abstract] [Full Text] [Related]
22. Hemoglobin--from F to A, and back. Adamson JW N Engl J Med; 1984 Apr; 310(14):917-9. PubMed ID: 6199671 [No Abstract] [Full Text] [Related]
23. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181 [No Abstract] [Full Text] [Related]
24. Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. Frost P; Kerbel RS; Hunt B; Man S; Pathak S Cancer Res; 1987 May; 47(10):2690-5. PubMed ID: 2436755 [TBL] [Abstract][Full Text] [Related]
25. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW N Engl J Med; 1990 Apr; 322(15):1037-45. PubMed ID: 1690857 [TBL] [Abstract][Full Text] [Related]
27. Treatment of thalassoemia--the current scenario. Datta S J Indian Med Assoc; 2002 Feb; 100(2):74-5. PubMed ID: 12206353 [No Abstract] [Full Text] [Related]
29. Heritable high frequency modulation of antigen expression in neoplastic cells exposed to 5-aza-2'-deoxycytidine or hydroxyurea: analysis and implications. Alvarez E; Elliott BE; Houghton AN; Kerbel RS Cancer Res; 1988 May; 48(9):2440-5. PubMed ID: 2451561 [TBL] [Abstract][Full Text] [Related]
31. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability. Huang Z; Louderback JG; King SB; Ballas SK; Kim-Shapiro DB Am J Hematol; 2001 Jul; 67(3):151-6. PubMed ID: 11391710 [TBL] [Abstract][Full Text] [Related]
32. Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains. DePass LR; Weaver EV J Toxicol Environ Health; 1982 Aug; 10(2):297-305. PubMed ID: 7143483 [TBL] [Abstract][Full Text] [Related]
34. Suppression of nuclear ADP-ribosyltransferase activity in Ehrlich ascites tumor cells by 5-azacytidine and its analogs. Hoshino J; Frahm J; Kröger H Biochem Biophys Res Commun; 1987 Jan; 142(2):468-74. PubMed ID: 2434095 [TBL] [Abstract][Full Text] [Related]
35. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia? Fathallah H; Sutton M; Atweh GF Ann N Y Acad Sci; 2005; 1054():228-37. PubMed ID: 16339670 [TBL] [Abstract][Full Text] [Related]
37. Fetal hemoglobin production in adult baboons by 5-azacytidine or by phenylhydrazine-induced hemolysis is associated with hypomethylation of globin gene DNA. DeSimone J; Heller P; Schimenti JC; Duncan CH Prog Clin Biol Res; 1983; 134():489-500. PubMed ID: 6198662 [TBL] [Abstract][Full Text] [Related]
38. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922 [TBL] [Abstract][Full Text] [Related]
39. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216 [TBL] [Abstract][Full Text] [Related]
40. Fetal Hemoglobin Induction by Epigenetic Drugs. Lavelle D; Engel JD; Saunthararajah Y Semin Hematol; 2018 Apr; 55(2):60-67. PubMed ID: 29958562 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]